Want to join the conversation?
$ABBV said argenx will conduct research and development through IND-enabling studies. Upon successful completion of these studies, $ABBV may exercise an exclusive option to license the ARGX-115 program and assume responsibility for further clinical development and commercialization.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.